Adding a new drug to hormone therapy for advanced breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether adding a second drug (neratinib) to standard hormone therapy can help women with a specific type of advanced breast cancer that has stopped responding to initial treatment. The goal is to see if the combination slows cancer growth better than hormone therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have advanced breast cancer that is estrogen receptor positive (ER+) and HER2 negative (HER2-).
- Your cancer has progressed after at least one line of treatment with hormone therapy and/or a CDK4/6 inhibitor.
- You have at least one tumor that can be seen on imaging and biopsied, and that biopsy shows your cancer is MLH1-low (a specific marker).
- You are not pregnant or breastfeeding, and you have a life expectancy of more than 1 year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
This trial tests whether taking neratinib for one extra year can reduce the risk of breast cancer returning in women who had a complete response (no cancer found) after initial treatment but still have high-risk features. It is for women with HER2-positive early breast cancer.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Hear when a new Metastatic Invasive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.